Hidden Conflicts? Pharma Payments to FDA Advisers After Drug Approvals Spark Ethical Concerns
In examining compensation records from drug companies to physicians who advised FDA, Science found widespread after-the-fact payments or research support to panel members. The agency's safeguards against potential conflicts of interest are not designed to prevent such future financial ties.
An investigative report uncovers little recognized and unpoliced potential conflicts of interest among those who serve on FDA advisory panels that review drugs. FDA may also have missed or judged insignificant financial ties physicians had before their service on the drug approval advisory panels.
Embezzlement of Research Funds Is a Problem, Investigators Say
A "significant number" of fraud cases involving research funds and academia have been uncovered in recent years, including professional exchanges which never actually took place, or projects that never came to fruition.
How Scientific Publishers Can End Bullying And Harassment In The Sciences
If the publishers of scientific journals everywhere enforced a universal code of ethics - if you violate the code, you cannot publish your scientific work - systematic bullies and harassers would be eliminated from their fields.
Repeat Offenders: When Scientific Fraudsters Slip Through the Cracks
Balancing due process with the academic community's right to know is no easy task, but critics say more could be done to weed out bad actors. Many universities halt investigations after an accused scientist departs, leaving future employers blind to the researcher’s history of allegations.